Recurrent chromosomal imbalances provide selective advantage to human embryonic stem cells under enhanced replicative stress conditions.


Journal

Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329

Informations de publication

Date de publication:
04 2021
Historique:
received: 15 07 2020
revised: 14 12 2020
accepted: 15 12 2020
pubmed: 19 12 2020
medline: 16 2 2022
entrez: 18 12 2020
Statut: ppublish

Résumé

Human embryonic stem cells (hESCs) and embryonal tumors share a number of common features, including a compromised G1/S checkpoint. Consequently, these rapidly dividing hESCs and cancer cells undergo elevated levels of replicative stress, inducing genomic instability that drives chromosomal imbalances. In this context, it is of interest that long-term in vitro cultured hESCs exhibit a remarkable high incidence of segmental DNA copy number gains, some of which are also highly recurrent in certain malignancies such as 17q gain (17q+). The selective advantage of DNA copy number changes in these cells has been attributed to several underlying processes including enhanced proliferation. We hypothesized that these recurrent chromosomal imbalances become rapidly embedded in the cultured hESCs through a replicative stress driven Darwinian selection process. To this end, we compared the effect of hydroxyurea-induced replicative stress vs normal growth conditions in an equally mixed cell population of isogenic euploid and 17q + hESCs. We could show that 17q + hESCs rapidly overtook normal hESCs. Our data suggest that recurrent chromosomal segmental gains provide a proliferative advantage to hESCs under increased replicative stress, a process that may also explain the highly recurrent nature of certain imbalances in cancer.

Identifiants

pubmed: 33336840
doi: 10.1002/gcc.22931
doi:

Substances chimiques

Hydroxyurea X6Q56QN5QC

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

272-281

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS114567
Pays : United States

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Young RA. Control of the embryonic stem cell state. Cell. 2011;144(6):940-954. https://doi.org/10.1016/j.cell.2011.01.032.
Ahuja AK, Jodkowska K, Teloni F, et al. A short G1 phase imposes constitutive replication stress and fork remodelling in mouse embryonic stem cells. Nat Commun. 2016;7:10660. https://doi.org/10.1038/ncomms10660.
Baker DEC, Harrison NJ, Maltby E, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol. 2007;25(2):207-215. https://doi.org/10.1038/nbt1285.
International Stem Cell Initiative, Amps K, Andrews PW, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011;29(12):1132-1144. https://doi.org/10.1038/nbt.2051.
Lund RJ, Närvä E, Lahesmaa R. Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet. 2012;13(10):732-744. https://doi.org/10.1038/nrg3271.
Zhang M, Cheng L, Jia Y, et al. Aneuploid embryonic stem cells exhibit impaired differentiation and increased neoplastic potential. EMBO J. 2016;35(21):2285-2300. https://doi.org/10.15252/embj.201593103.
Vanhauwaert S, Decaesteker B, De Brouwer S, et al. In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors. Sci Rep. 2018;8(1):17468. https://doi.org/10.1038/s41598-018-35868-5.
Warrier S, Van der Jeught M, Duggal G, et al. Direct comparison of distinct naive pluripotent states in human embryonic stem cells. Nat Commun. 2017;8:15055. https://doi.org/10.1038/ncomms15055.
Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol. 1963;17:299-313. https://doi.org/10.1083/jcb.17.2.299.
Lenth RV. Least-squares means: the R package lsmeans. J Stat Softw. 2016;69(1):1-33. https://doi.org/10.18637/jss.v069.i01.
Sante T, Vergult S, Volders P-J, et al. ViVar: a comprehensive platform for the analysis and visualization of structural genomic variation. PLOS One. 2014;9(12):e113800. https://doi.org/10.1371/journal.pone.0113800.
Lefever S, Vandesompele J, Speleman F, Pattyn F. RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res. 2009;37(Database issue):D942-D945. https://doi.org/10.1093/nar/gkn777.
Vynck M, Vandesompele J, Nijs N, Menten B, De Ganck A, Thas O. Flexible analysis of digital PCR experiments using generalized linear mixed models. Biomol Detect Quantif. 2016;9:1-13. https://doi.org/10.1016/j.bdq.2016.06.001.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. https://doi.org/10.1073/pnas.0506580102.
Vandesompele J, Michels E, Preter KD, et al. Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. Int J Cancer. 2008;122(5):1177-1182. https://doi.org/10.1002/ijc.23156.
Singh A, Xu Y-J. The cell killing mechanisms of Hydroxyurea. Genes. 2016;7(11):99-99. https://doi.org/10.3390/genes7110099.
Whittington N, Cunningham D, Le T-K, De Maria D, Silva EM. Sox21 regulates the progression of neuronal differentiation in a dose-dependent manner. Dev Biol. 2015;397(2):237-247. https://doi.org/10.1016/j.ydbio.2014.11.012.
Enver T, Soneji S, Joshi C, et al. Cellular differentiation hierarchies in normal and culture-adapted human embryonic stem cells. Hum Mol Genet. 2005;14(21):3129-3140. https://doi.org/10.1093/hmg/ddi345.
Werbowetski-Ogilvie TE, Bossé M, Stewart M, et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol. 2009;27(1):91-97. https://doi.org/10.1038/nbt.1516.
Yang S, Lin G, Tan Y-Q, et al. Tumor progression of culture-adapted human embryonic stem cells during long-term culture. Genes Chromosomes Cancer. 2008;47(8):665-679. https://doi.org/10.1002/gcc.20574.
Sheikine Y, Genega E, Melamed J, Lee P, Reuter VE, Ye H. Molecular genetics of testicular germ cell tumors. Am J Cancer Res. 2012;2(2):153-167.
Bown N, Cotterill S, Łastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with Neuroblastoma. N Engl J Med. 1999;340(25):1954-1961. https://doi.org/10.1056/NEJM199906243402504.
Decaesteker B, Denecker G, Van Neste C, et al. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nat Commun. 2018;9(1):4866. https://doi.org/10.1038/s41467-018-06699-9.
Herold S, Kalb J, Büchel G, et al. Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature. 2019;567(7749):545-549. https://doi.org/10.1038/s41586-019-1030-9.
Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008;100:133-158. https://doi.org/10.1016/S0065-230X(08)00005-5.
Zeltner N, Studer L. Pluripotent stem cell-based disease modeling: current hurdles and future promise. Curr Opin Cell Biol. 2015;37:102-110. https://doi.org/10.1016/j.ceb.2015.10.008.

Auteurs

Liselot M Mus (LM)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Stéphane Van Haver (S)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Mina Popovic (M)

Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Ghent, Belgium.

Wim Trypsteen (W)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Steve Lefever (S)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Nadja Zeltner (N)

Center for Molecular Medicine, Department of Biochemistry & Molecular Biology and Department of Cellular Biology, University of Georgia, Athens, Georgia, USA.

Yudelca Ogando (Y)

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA.

Eva Z Jacobs (EZ)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Geertrui Denecker (G)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Ellen Sanders (E)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Christophe Van Neste (C)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Suzanne Vanhauwaert (S)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Bieke Decaesteker (B)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Dieter Deforce (D)

Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.

Filip Van Nieuwerburgh (F)

Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.

Pieter Mestdagh (P)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Jo Vandesompele (J)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Björn Menten (B)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Katleen De Preter (K)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Lorenz Studer (L)

The Center for Stem Cell Biology, Sloan Kettering Institute, New York, USA.
Developmental Biology Program, Sloan Kettering Institute, New York, USA.

Björn Heindryckx (B)

Ghent-Fertility and Stem Cell Team (G-FaST), Department for Reproductive Medicine, Ghent University Hospital, Ghent, Belgium.

Kaat Durinck (K)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Stephen Roberts (S)

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA.

Frank Speleman (F)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ghent University, Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH